Genetic diagnosis of hepatic steatosis
AssigneeBoard of Regents, The University of Texas System
InventorsHelen H Hobbs, Jonathan C Cohen
Life of this patent
Estimating the term…
Abstract
Disclosed are methods of identifying a genetic variant in a person determined to have or be predisposed having a fatty liver by determining whether the person has PNPLA3-I148M. Also disclosed are methods of identifying a genetic variant in a person by determining whether the person has PNPLA3-I148M; and prescribing to the person a treatment to reduce liver fat or associated inflammation.
Claims20
A method for determining a genetic marker in a PNPLA3 gene of a human and treating the human for high hepatic fat content, the method comprising the steps:
- (a) determining that the genome of the human comprises a genetic marker of PNPLA3-I148M by detecting a G allele at SNP rs738409;
- (b) identifying the human as having a high hepatic fat content based on the detection of the G allele at SNP rs738409;
- and
- (c) treating the human identified in (b) as having a high hepatic fat content with an antiobesity drug that is orlistat, sibutramine, exenatide, pramlintide or rimonabant.
A method for determining a genetic marker in a PNPLA3 gene of a human and treating the human for high hepatic fat content, the method comprising the steps:
- (a) determining that the genome of the human comprises a genetic marker of PNPLA3-I148M by detecting a G allele at SNP rs738409;
- (b) identifying the human as having a high hepatic fat content based on the detection of the G allele at SNP rs738409;
- and
- (c) treating the human identified in (b) as having a high hepatic fat content with an anti-diabetic drug that is a thiazolidinedione, metformin or glimepiride.
Dependencies are inferred from the claim text.